ArticleBlood advances2022
Low rate of subsequent malignant neoplasms after CD19 CAR T-cell therapy.
Abstract read
In one paragraph
Article in Blood advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial.Journal of hematology & oncology · 2024Trial
- Spectrum, pathobiology, mechanistic insights and diagnostic challenges of post-CAR T cell therapy lymphoproliferative disorders.Nature reviews. Clinical oncology · 2026Review
- The evolving landscape of CAR T cell therapy in children and young adults with B cell acute lymphoblastic leukemia.Molecular therapy. Oncology · 2026Review
- Data-informed optimization of CAR T-cell therapy long-term follow-up.Journal for immunotherapy of cancer · 2026Article
- The quintessential role for CAR T cell therapy in children, adolescents and young adults with cancer.Nature reviews. Clinical oncology · 2026Review
- Secondary Malignancies of Chimeric Antigen Receptor T-cell Therapy: A Multidimensional Analysis of Mechanisms, Risk Factors, and Treatment Strategies.Anti-cancer agents in medicinal chemistry · 2026Review
- A Decade of Transformation in the Management of Childhood Acute Lymphoblastic Leukemia: From Conventional Chemotherapy to Precision Medicine.Pediatric reports · 2025Review
- Chimeric Antigen Receptor-T Cells in the Modern Era of Chronic Lymphocytic Leukemia Treatment.Cancers · 2025Review
- Review
- Therapy-Related Myeloid Neoplasms: Complex Interactions among Cytotoxic Therapies, Genetic Factors, and Aberrant Microenvironment.Blood cancer discovery · 2024Review
- The Current Landscape of Secondary Malignancies after CAR T-Cell Therapies: How Could Malignancies Be Prevented?International journal of molecular sciences · 2024Review
- Risk of T-cell malignancy after CAR T-cell therapy in children, adolescents, and young adults.Blood advances · 2024Article
- Characterization of second primary malignancies post CAR T-cell therapy: real-world insights from the two global pharmacovigilance databases of FAERS and VigiBase.EClinicalMedicine · 2024Article
- Genotoxicity Associated with Retroviral CAR Transduction of ATM-Deficient T Cells.Blood cancer discovery · 2024Article
- Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy.The New England journal of medicine · 2024Article
- Bispecific antibodies and CAR-T cells: dueling immunotherapies for large B-cell lymphomas.Blood cancer journal · 2024Review
- Unanswered questions following reports of secondary malignancies after CAR-T cell therapy.Nature medicine · 2024Article
- Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL.Hematology. American Society of Hematology. Education Program · 2023Review
- Early and Late Toxicities of Chimeric Antigen Receptor T-Cells.Hematology/oncology clinics of North America · 2023Review
- Chimeric Antigen Receptor T Cells as Salvage Therapy for Post-Chimeric Antigen Receptor T Cell Failure.Transplantation and cellular therapy · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Emily M HsiehDivision of Hematology/Oncology/Transplantation and Cellular Therapy, Children's Hospital Los Angeles Cancer and Blood Disease Institute, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA.ORCID 0000-0001-5088-7621
Regina M MyersDivision of Oncology, Cell Therapy and Transplant Section, Children's Hospital of Philadelphia, Philadelphia, PA.ORCID 0000-0002-2542-2061
Bonnie YatesPediatric Oncology Branch, National Cancer Institute/Center for Cancer Research, National Institutes of Health, Bethesda, MD.
Colleen AnnesleyDivision of Hematology/Oncology, University of Washington, Seattle Children's Hospital, Seattle, WA.
Samuel JohnBiostatistics and Data Management Section, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Agne TaraseviciuteDivision of Hematology/Oncology/Transplantation and Cellular Therapy, Children's Hospital Los Angeles Cancer and Blood Disease Institute, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA.
Seth M SteinbergBiostatistics and Data Management Section, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Jennifer SheppardDivision of Pediatric Hematology/Oncology, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX.
Perry ChungDivision of Oncology, Cell Therapy and Transplant Section, Children's Hospital of Philadelphia, Philadelphia, PA.
Lee ChenDivision of Hematology/Oncology/Transplantation and Cellular Therapy, Children's Hospital Los Angeles Cancer and Blood Disease Institute, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA.
Daniel W LeePediatric Oncology Branch, National Cancer Institute/Center for Cancer Research, National Institutes of Health, Bethesda, MD.ORCID 0000-0002-3249-9796
Amanda DiNofiaDivision of Oncology, Cell Therapy and Transplant Section, Children's Hospital of Philadelphia, Philadelphia, PA.
Stephan A GruppDivision of Oncology, Cell Therapy and Transplant Section, Children's Hospital of Philadelphia, Philadelphia, PA.
Michael R VernerisPediatric Hematology/Oncology/BMT-CT, University of Colorado, Children's Hospital Colorado, Aurora, CO.
Theodore W LaetschDivision of Oncology, Cell Therapy and Transplant Section, Children's Hospital of Philadelphia, Philadelphia, PA.
Deepa BhojwaniDivision of Hematology/Oncology/Transplantation and Cellular Therapy, Children's Hospital Los Angeles Cancer and Blood Disease Institute, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA.
Patrick A BrownDivision of Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD; and.ORCID 0000-0002-8653-1069
Michael A PulsipherDivision of Hematology/Oncology/Transplantation and Cellular Therapy, Children's Hospital Los Angeles Cancer and Blood Disease Institute, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA.ORCID 0000-0003-3030-8420
Susan R RheingoldDivision of Oncology, Cell Therapy and Transplant Section, Children's Hospital of Philadelphia, Philadelphia, PA.ORCID 0000-0001-8025-6767
Rebecca A GardnerDivision of Hematology/Oncology, University of Washington, Seattle Children's Hospital, Seattle, WA.
Lia GorePediatric Hematology/Oncology/BMT-CT, University of Colorado, Children's Hospital Colorado, Aurora, CO.ORCID 0000-0002-2546-4616
Nirali N ShahPediatric Oncology Branch, National Cancer Institute/Center for Cancer Research, National Institutes of Health, Bethesda, MD.ORCID 0000-0002-8474-9080
Adam J LambleDivision of Hematology/Oncology, University of Washington, Seattle Children's Hospital, Seattle, WA.ORCID 0000-0001-5088-7621
Funding
University of Colorado Cancer Center Support Grant - Lung Cancer Patient-Derived Xenografts with Autologous Human Immune SystemsP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · 1988 to 2026
$117.0MImmunotherapeutic approaches to treat pediatric hematologic malignanciesZIABC011823 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI SHAH, NIRALI · 2019 to 2025
$6.1MIntramural NIH HHS ZIA BC011823NCI NIH HHS P30 CA046934
Abstract
PubMed holds no abstract for this paper.
Indexed as
Immunotherapy, AdoptiveNeoplasmsAntigens, CD19HumansReceptors, Antigen, T-CellAntigens, CD19Receptors, Antigen, T-Cell
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.